FOLH1 and prostate carcinoma: This in vitro study investigated the differences in cell viability and proliferation between the 2D and 3D models of the two prostate cancer cell lines, PC-3 and LNCaP, after treatment with the already clinically used radioligand therapy agent, [177Lu]Lu-PSMA-I&T.